Tirzepatide,is an antidiabetic medication used for the treatment of type 2 diabetes. Tirzepatide is administered through subcutaneous injection (under the skin).
The most common side effects include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood-sugar control. After a person has eaten, these hormones are secreted by cells of the intestines, and in turn cause the secretion of insulin. Tirzepatide is a GIP-analogue that activates both the GLP-1 and GIP receptors, leading to improved blood-sugar control.
Tirzepatide was approved for medical use in the United States in May 2022, in the European Union in September 2022, in Canada in November 2022,and in Australia in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.